BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $MRK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04634877-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:Pembrolizumab readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study of Pembrolizumab (MK-3475) in Combination With Adjuvant C
 hemotherapy With or Without Radiotherapy in Participants With Newly Diagno
 sed Endometrial Cancer After Surgery With …\n\nPrimary completion date: 
 2026-11-20 (estimated)\nOriginally planned: 2025-06-18 (+17.1 months)\nPha
 se 3 · Oncology · Endometrial Neoplasms\nEnrollment: 990 · Sites: 231\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT04634877\nhttps://clinicaltrials.gov/study/NCT0463487
 7
URL:https://datacutoff.com/radar.html?nct=NCT04634877
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05609968-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270112
DTEND;VALUE=DATE:20270113
SUMMARY:Sacituzumab Govitecan readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab
  Govitecan in Combination With Pembrolizumab for Participants With Metasta
 tic Non-small Cell Lung Cancer (NSCLC) Wit…\n\nPrimary completion date: 
 2027-01-12 (estimated)\nPhase 3 · Oncology · Carcinoma\, Non-Small-Cell 
 Lung\nEnrollment: 614 · Sites: 180\n\nPrimary completion = last participa
 nt's primary-endpoint data collected\; topline results usually follow week
 s to months later. Sponsor-reported\, often an estimate. Not investment ad
 vice.\n\nhttps://datacutoff.com/radar.html?nct=NCT05609968\nhttps:
 //clinicaltrials.gov/study/NCT05609968
URL:https://datacutoff.com/radar.html?nct=NCT05609968
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04199689-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:9vHPV Vaccine readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Efficacy Against Oral Persistent Infection\, Immunogenicity and
  Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 2
 0-45 Years (V503-049)\n\nPrimary completion date: 2027-01-15 (estimated)\n
 Originally planned: 2025-12-20 (+12.8 months)\nPhase 3 · Infectious · Pa
 pillomavirus Infections\nEnrollment: 6033 · Sites: 103\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT04199689\nhttps://clinicaltrials.gov/study/NCT04199689
URL:https://datacutoff.com/radar.html?nct=NCT04199689
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04241185-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pembrolizumab readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Efficacy and Safety of Pembrolizumab (MK-3475) in Combination W
 ith Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Ca
 ncer (MIBC) (MK-3475-992/KEYNOTE-992)\n\nPrimary completion date: 2027-01-
 31 (estimated)\nOriginally planned: 2026-10-10 (+3.7 months)\nPhase 3 · O
 ncology · Urinary Bladder Neoplasms\nEnrollment: 520 · Sites: 134\n\nPri
 mary completion = last participant's primary-endpoint data collected\; top
 line results usually follow weeks to months later. Sponsor-reported\, ofte
 n an estimate. Not investment advice.\n\nhttps://datacutoff.com/ra
 dar.html?nct=NCT04241185\nhttps://clinicaltrials.gov/study/NCT04241185
URL:https://datacutoff.com/radar.html?nct=NCT04241185
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03407144-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270212
DTEND;VALUE=DATE:20270213
SUMMARY:pembrolizumab readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Safety and Efficacy of Pembrolizumab (MK-3475) in Children and 
 Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)\n\n
 Primary completion date: 2027-02-12 (estimated)\nOriginally planned: 2023-
 11-24 (+38.6 months)\nPhase 2 · Oncology · Hodgkin Lymphoma\nEnrollment:
  340 · Sites: 93\n\nPrimary completion = last participant's primary-endpo
 int data collected\; topline results usually follow weeks to months later.
  Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps://t
 rialsonar.netlify.app/radar.html?nct=NCT03407144\nhttps://clinicaltrials.g
 ov/study/NCT03407144
URL:https://datacutoff.com/radar.html?nct=NCT03407144
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07486960-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270217
DTEND;VALUE=DATE:20270218
SUMMARY:Tulisokibart readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study to Evaluate Tulisokibart in Adults With Psoriatic Arthrit
 is (MK-7240-015)\n\nPrimary completion date: 2027-02-17 (estimated)\nOrigi
 nally planned: 2027-08-13 (-5.8 months)\nPhase 2 · Immuno · Psoriatic Ar
 thritis\nEnrollment: 140 · Sites: 50\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07486960\nhttp
 s://clinicaltrials.gov/study/NCT07486960
URL:https://datacutoff.com/radar.html?nct=NCT07486960
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04976634-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270322
DTEND;VALUE=DATE:20270323
SUMMARY:Pembrolizumab readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in
  Solid Tumors (MK-6482-016)\n\nPrimary completion date: 2027-03-22 (estima
 ted)\nOriginally planned: 2026-07-07 (+8.5 months)\nPhase 2 · Oncology ·
  Neoplasm Malignant\nEnrollment: 730 · Sites: 57\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04
 976634\nhttps://clinicaltrials.gov/study/NCT04976634
URL:https://datacutoff.com/radar.html?nct=NCT04976634
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07133633-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270329
DTEND;VALUE=DATE:20270330
SUMMARY:Tulisokibart readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Clinical Study of Tulisokibart (MK-7240) to Treat Radiographi
 c Axial Spondyloarthritis (MK-7240-013)\n\nPrimary completion date: 2027-0
 3-29 (estimated)\nOriginally planned: 2027-06-15 (-2.6 months)\nPhase 2 ·
  Immuno · Radiographic Axial Spondyloarthritis\nEnrollment: 315 · Sites:
  108\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT07133633\nhttps://clinicaltrials.gov/study/NCT0
 7133633
URL:https://datacutoff.com/radar.html?nct=NCT07133633
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04665037-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Posaconazole IV 6 mg/kg readout (P2) · Merck Sharp & Dohme LLC $MR
 K
DESCRIPTION:Posaconazole (MK-5592) Intravenous and Oral in Children (<2 Yea
 rs) With Invasive Fungal Infection (MK-5592-127)\n\nPrimary completion dat
 e: 2027-03-31 (estimated)\nOriginally planned: 2023-07-17 (+44.4 months)\n
 Phase 2 · Infectious · Invasive Fungal Infection\nEnrollment: 40 · Site
 s: 26\n\nPrimary completion = last participant's primary-endpoint data col
 lected\; topline results usually follow weeks to months later. Sponsor-rep
 orted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.ne
 tlify.app/radar.html?nct=NCT04665037\nhttps://clinicaltrials.gov/study/NCT
 04665037
URL:https://datacutoff.com/radar.html?nct=NCT04665037
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02628067-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270504
DTEND;VALUE=DATE:20270505
SUMMARY:pembrolizumab readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study of Pembrolizumab (MK-3475) in Participants With Advanced 
 Solid Tumors (MK-3475-158/KEYNOTE-158)\n\nPrimary completion date: 2027-05
 -04 (estimated)\nOriginally planned: 2018-04 (+109.1 months)\nPhase 2 · O
 ncology · Advanced Cancer\, Anal Carcinoma\, Anal Cancer\nEnrollment: 160
 9 · Sites: 0\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://trial
 sonar.netlify.app/radar.html?nct=NCT02628067\nhttps://clinicaltrials.gov/s
 tudy/NCT02628067
URL:https://datacutoff.com/radar.html?nct=NCT02628067
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04380636-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Pembrolizumab readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study of Pembrolizumab With Concurrent Chemoradiation Therapy F
 ollowed by Pembrolizumab With or Without Olaparib in Stage III Non-Small C
 ell Lung Cancer (NSCLC) (MK-7339-012/KEYLY…\n\nPrimary completion date: 
 2027-05-05 (estimated)\nOriginally planned: 2026-07-06 (+10.0 months)\nPha
 se 3 · Oncology · Lung Neoplasms\, Carcinoma\, Non-Small-Cell Lung\nEnro
 llment: 870 · Sites: 205\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://trialsonar.netlify.app/radar.html?nct=NCT04380636\nhttps://clinical
 trials.gov/study/NCT04380636
URL:https://datacutoff.com/radar.html?nct=NCT04380636
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06428396-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270505
DTEND;VALUE=DATE:20270506
SUMMARY:Belzutifan readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Me
 tastatic Breast Cancer (MK-6482-029/LITESPARK-029)\n\nPrimary completion d
 ate: 2027-05-05 (estimated)\nOriginally planned: 2027-06-24 (-1.6 months)\
 nPhase 2 · Oncology · Metastatic Breast Cancer\nEnrollment: 120 · Sites
 : 41\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT06428396\nhttps://clinicaltrials.gov/study/NCT0
 6428396
URL:https://datacutoff.com/radar.html?nct=NCT06428396
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06074588-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270510
DTEND;VALUE=DATE:20270511
SUMMARY:Sacituzumab tirumotecan readout (P3) · Merck Sharp & Dohme LLC $MR
 K
DESCRIPTION:Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previo
 usly Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer
  (NSCLC) With EGFR Mutations or Other Geno…\n\nPrimary completion date: 
 2027-05-10 (estimated)\nPhase 3 · Oncology · Non-small Cell Lung Cancer 
 (NSCLC)\nEnrollment: 556 · Sites: 195\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06074588\nhtt
 ps://clinicaltrials.gov/study/NCT06074588
URL:https://datacutoff.com/radar.html?nct=NCT06074588
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05624554-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270519
DTEND;VALUE=DATE:20270520
SUMMARY:Nemtabrutinib readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants
  With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic 
 Lymphoma (CLL/SLL) Without TP53 Aberration…\n\nPrimary completion date: 
 2027-05-19 (estimated)\nOriginally planned: 2027-02-20 (+2.9 months)\nPhas
 e 3 · Oncology · Chronic Lymphocytic Leukemia\, Small Lymphocytic Lympho
 ma\nEnrollment: 300 · Sites: 97\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT05624554\nhttps://c
 linicaltrials.gov/study/NCT05624554
URL:https://datacutoff.com/radar.html?nct=NCT05624554
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05173987-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270527
DTEND;VALUE=DATE:20270528
SUMMARY:pembrolizumab readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatc
 h Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-
 3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)\n\nPrimary completion date: 2027
 -05-27 (estimated)\nOriginally planned: 2026-07-17 (+10.3 months)\nPhase 3
  · Oncology · Endometrial Neoplasms\nEnrollment: 280 · Sites: 194\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT05173987\nhttps://clinicaltrials.gov/study/NCT05173987
URL:https://datacutoff.com/radar.html?nct=NCT05173987
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07862595-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270610
DTEND;VALUE=DATE:20270611
SUMMARY:MK-6916 readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Clinical Trial of MK-6916 in Participants With Pain After Bun
 ion Removal Surgery (MK-6916-007)\n\nPrimary completion date: 2027-06-10 (
 estimated)\nPhase 2 · Neuro · Pain Management\nEnrollment: 380 · Sites:
  9\n\nPrimary completion = last participant's primary-endpoint data collec
 ted\; topline results usually follow weeks to months later. Sponsor-report
 ed\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netli
 fy.app/radar.html?nct=NCT07862595\nhttps://clinicaltrials.gov/study/NCT078
 62595
URL:https://datacutoff.com/radar.html?nct=NCT07862595
CATEGORIES:Neuro,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06655883-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270624
DTEND;VALUE=DATE:20270625
SUMMARY:Suvorexant readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of Suvorexant (MK-4305) for the Treatment of Insomnia D
 isorder in Participants With Opioid Use Disorder (MK-4305-098)\n\nPrimary 
 completion date: 2027-06-24 (estimated)\nOriginally planned: 2026-08-17 (+
 10.2 months)\nPhase 3 · Neuro · Insomnia\nEnrollment: 300 · Sites: 13\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://trialsonar.netlify.a
 pp/radar.html?nct=NCT06655883\nhttps://clinicaltrials.gov/study/NCT0665588
 3
URL:https://datacutoff.com/radar.html?nct=NCT06655883
CATEGORIES:Neuro,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06312176-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270711
DTEND;VALUE=DATE:20270712
SUMMARY:Sacituzumab tirumotecan readout (P3) · Merck Sharp & Dohme LLC $MR
 K
DESCRIPTION:A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent 
 and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physic
 ian's Choice in Participants With HR+/HER2…\n\nPrimary completion date: 
 2027-07-11 (estimated)\nPhase 3 · Oncology · Breast Neoplasms\nEnrollmen
 t: 1200 · Sites: 259\n\nPrimary completion = last participant's primary-e
 ndpoint data collected\; topline results usually follow weeks to months la
 ter. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps
 ://trialsonar.netlify.app/radar.html?nct=NCT06312176\nhttps://clinicaltria
 ls.gov/study/NCT06312176
URL:https://datacutoff.com/radar.html?nct=NCT06312176
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079879-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Bomedemstat readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Avai
 lable Therapy (BAT) in Participants With Essential Thrombocythemia and an 
 Inadequate Response or Intolerance of Hydr…\n\nPrimary completion date: 
 2027-07-14 (estimated)\nOriginally planned: 2028-08-18 (-13.2 months)\nPha
 se 3 · Cardio-Met · Essential Thrombocythemia\nEnrollment: 340 · Sites:
  161\n\nPrimary completion = last participant's primary-endpoint data coll
 ected\; topline results usually follow weeks to months later. Sponsor-repo
 rted\, often an estimate. Not investment advice.\n\nhttps://trialsonar.net
 lify.app/radar.html?nct=NCT06079879\nhttps://clinicaltrials.gov/study/NCT0
 6079879
URL:https://datacutoff.com/radar.html?nct=NCT06079879
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07044297-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270722
DTEND;VALUE=DATE:20270723
SUMMARY:MK-8527 readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Clinical Study of MK-8527 to Prevent Human Immunodeficiency V
 irus Type 1 (HIV-1) (MK-8527-011)\n\nPrimary completion date: 2027-07-22 (
 estimated)\nOriginally planned: 2027-10-20 (-3.0 months)\nPhase 3 · Infec
 tious · Human Immunodeficiency Virus (HIV)\, HIV Pre-Exposure Prophylaxis
 \nEnrollment: 4390 · Sites: 81\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT07044297\nhttps://cl
 inicaltrials.gov/study/NCT07044297
URL:https://datacutoff.com/radar.html?nct=NCT07044297
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06891066-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:ISL readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of Islatravir (ISL) and Ulonivirine (ULO) Once Weekly (
 QW) in Virologically Suppressed Adults With Human Immunodeficiency Virus T
 ype 1 (HIV-1) (MK-8591B-060)\n\nPrimary completion date: 2027-08-10 (estim
 ated)\nOriginally planned: 2027-10-01 (-1.7 months)\nPhase 2 · Infectious
  · Human Immunodeficiency Virus Type 1 (HIV-1) Infection\nEnrollment: 150
  · Sites: 23\n\nPrimary completion = last participant's primary-endpoint 
 data collected\; topline results usually follow weeks to months later. Spo
 nsor-reported\, often an estimate. Not investment advice.\n\nhttps://trial
 sonar.netlify.app/radar.html?nct=NCT06891066\nhttps://clinicaltrials.gov/s
 tudy/NCT06891066
URL:https://datacutoff.com/radar.html?nct=NCT06891066
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05139017-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:Zilovertamab vedotin readout (P2/3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of Zilovertamab Vedotin (MK-2140) in Combination With S
 tandard of Care in Participants With Relapsed or Refractory Diffuse Large 
 B-Cell Lymphoma (rrDLBCL) (MK-2140-003)\n\nPrimary completion date: 2027-0
 9-24 (estimated)\nOriginally planned: 2024-12-16 (+33.2 months)\nPhase 2/3
  · Oncology · DLBCL\, Diffuse Large B-Cell Lymphoma\nEnrollment: 290 · 
 Sites: 135\n\nPrimary completion = last participant's primary-endpoint dat
 a collected\; topline results usually follow weeks to months later. Sponso
 r-reported\, often an estimate. Not investment advice.\n\nhttps://trialson
 ar.netlify.app/radar.html?nct=NCT05139017\nhttps://clinicaltrials.gov/stud
 y/NCT05139017
URL:https://datacutoff.com/radar.html?nct=NCT05139017
CATEGORIES:Oncology,Phase 2/3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06456346-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:Bomedemstat readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-35
 43-007)\n\nPrimary completion date: 2027-09-28 (estimated)\nOriginally pla
 nned: 2029-05-14 (-19.5 months)\nPhase 3 · Cardio-Met · Essential Thromb
 ocythemia\nEnrollment: 300 · Sites: 171\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06456346\nh
 ttps://clinicaltrials.gov/study/NCT06456346
URL:https://datacutoff.com/radar.html?nct=NCT06456346
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07614984-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:MK-7262 readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Clinical Trial of MK-7262 and Enlicitide in Participants With
  High Lipoprotein(a) (MK-7262-004)\n\nPrimary completion date: 2027-10-12 
 (estimated)\nPhase 2 · Cardio-Met · Lipoprotein(a)\nEnrollment: 750 · S
 ites: 77\n\nPrimary completion = last participant's primary-endpoint data 
 collected\; topline results usually follow weeks to months later. Sponsor-
 reported\, often an estimate. Not investment advice.\n\nhttps://trialsonar
 .netlify.app/radar.html?nct=NCT07614984\nhttps://clinicaltrials.gov/study/
 NCT07614984
URL:https://datacutoff.com/radar.html?nct=NCT07614984
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07071623-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:MK-8527 readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type
  1 (HIV-1) (MK-8527-010)\n\nPrimary completion date: 2027-10-18 (estimated
 )\nOriginally planned: 2028-01-14 (-2.9 months)\nPhase 3 · Infectious · 
 Human Immunodeficiency Virus (HIV)\, HIV Pre-Exposure Prophylaxis\nEnrollm
 ent: 4580 · Sites: 30\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://trialsonar.netlify.app/radar.html?nct=NCT07071623\nhttps://clinicaltri
 als.gov/study/NCT07071623
URL:https://datacutoff.com/radar.html?nct=NCT07071623
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07895524-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271019
DTEND;VALUE=DATE:20271020
SUMMARY:MK-8690 readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Clinical Trial of MK-8690 in Participants With Rheumatoid Art
 hritis (MK-8690-004)\n\nPrimary completion date: 2027-10-19 (estimated)\nP
 hase 2 · Immuno · Rheumatoid Arthritis\nEnrollment: 60 · Sites: 0\n\nPr
 imary completion = last participant's primary-endpoint data collected\; to
 pline results usually follow weeks to months later. Sponsor-reported\, oft
 en an estimate. Not investment advice.\n\nhttps://datacutoff.com/r
 adar.html?nct=NCT07895524\nhttps://clinicaltrials.gov/study/NCT07895524
URL:https://datacutoff.com/radar.html?nct=NCT07895524
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04624204-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Pembrolizumab 200 mg readout (P3) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:Placebo-controlled\, Study of Concurrent Chemoradiation Therapy
  With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagno
 sed Treatment-Naïve Limited-Stage Small Cel…\n\nPrimary completion date
 : 2027-10-28 (estimated)\nPhase 3 · Oncology · Small Cell Lung Cancer\nE
 nrollment: 672 · Sites: 187\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT04624204\nhttps://clini
 caltrials.gov/study/NCT04624204
URL:https://datacutoff.com/radar.html?nct=NCT04624204
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463183-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:MK-8690 readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study to Evaluate Efficacy and Safety of MK-8690 in Participa
 nts With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)\n\
 nPrimary completion date: 2027-10-28 (estimated)\nPhase 2 · GI·Renal·He
 me · Colitis Ulcerative\, Ulcerative Colitis\nEnrollment: 100 · Sites: 4
 3\n\nPrimary completion = last participant's primary-endpoint data collect
 ed\; topline results usually follow weeks to months later. Sponsor-reporte
 d\, often an estimate. Not investment advice.\n\nhttps://trialsonar.netlif
 y.app/radar.html?nct=NCT07463183\nhttps://clinicaltrials.gov/study/NCT0746
 3183
URL:https://datacutoff.com/radar.html?nct=NCT07463183
CATEGORIES:GI·Renal·Heme,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979596-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271104
DTEND;VALUE=DATE:20271105
SUMMARY:Opevesostat readout (P2) · Merck Sharp & Dohme LLC $MRK
DESCRIPTION:A Study of MK-5684 in People With Certain Solid Tumors (MK-5684
 -015/OMAHA-015)\n\nPrimary completion date: 2027-11-04 (estimated)\nOrigin
 ally planned: 2030-07-17 (-32.4 months)\nPhase 2 · Oncology · Malignant 
 Neoplasm\nEnrollment: 250 · Sites: 60\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06979596\nhtt
 ps://clinicaltrials.gov/study/NCT06979596
URL:https://datacutoff.com/radar.html?nct=NCT06979596
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
